Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause

NCT06172751 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06172751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06172751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
December 15, 2023
Completion date
April 26, 2024
Enrollment
250 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypereosinophilic syndrome (hes)